About PhaseBio Pharmaceuticals
PhaseBio Pharmaceuticals (NASDAQ: PHAS) develops drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability, and physical characteristics of molecules for ease of administration. It was founded in 2002 and is based in Malvern, Pennsylvania.
PhaseBio Pharmaceuticals Patents
PhaseBio Pharmaceuticals has filed 30 patents.
Cardiac arrhythmia, Transcription factors, Rare diseases, Clusters of differentiation, Muscular dystrophy
Cardiac arrhythmia, Transcription factors, Rare diseases, Clusters of differentiation, Muscular dystrophy
Latest PhaseBio Pharmaceuticals News
Jul 19, 2023
Share this article Share this article According to DelveInsight, the hypertension market in the 7MM is expected to significantly change during the study period 2019–2032. While the hypertension market has generally shown a positive trend, certain factors could potentially contribute to a decline involving low compliance with antihypertensives or poor access to newer medications. LAS VEGAS, July 19, 2023 /PRNewswire/ -- DelveInsight's Hypertension Market Insights report includes a comprehensive understanding of current treatment practices, hypertension emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the Hypertension Market Report As per DelveInsight analysis, the hypertension market is expected to grow positively at a significant CAGR during the study period (2019–2032). According to World Health Organization (2023), the prevalence of hypertension shows regional and income group variations, with the WHO Region of the Americas exhibiting the lowest prevalence of hypertension at 18%. Different regions and countries display varying rates of hypertension. Leading hypertension companies such as JeniVision, Inc., AI Therapeutics, Inc., Apnimed, AstraZeneca, Aerovate Therapeutics, Merck Sharp & Dohme LLC, AbbVie, Alnylam Pharmaceuticals, Gossamer Bio Inc., Insmed Incorporated, Actelion, Boehringer Ingelheim, Acceleron Pharma, Bayer, Perfuse Therapeutics, Inc., KBP Biosciences, Novartis, Gmax Biopharm LLC, United Therapeutics, Tarsier Pharma, and others are developing novel hypertension drugs that can be available in the hypertension market in the coming years. Some key therapies for hypertension treatment include JV-GL1, LAM-001, AD113, AZD3427, AV-101, CIN-107, MK-5475, AGN-193408 SR, ALN-AGT01, GB002, Treprostinil Palmitil, Macitentan, BI 685509, Sotatercept, BAY63-2521, PER-001, KBP-5074, LTP001, Q4W GMA301 IV injections, Ralinepag, TRS01, and others. Discover which therapies are expected to grab the major hypertension market share @ Hypertension Market Report Hypertension Overview Hypertension, often known as high blood pressure, is a common medical condition marked by consistently high blood pressure readings. Primary hypertension and secondary hypertension are the two common types of hypertension. The most common type of hypertension has multiple causes, including genetics, lifestyle factors, and aging. Secondary hypertension is caused by an underlying medical problem. Elevated, Stage 1, Stage 2, and hypertensive crisis are the major classifications for the condition. Hypertension is diagnosed by monitoring a person's blood pressure to see if it is above the usual range. To acquire reliable readings, a healthcare worker often uses a blood pressure cuff, sphygmomanometer, or automated blood pressure monitoring device. Diagnosis of hypertension is difficult due to its silent nature, with no obvious symptoms in the early stages, which leads to underdiagnosis. Hypertension Epidemiology Segmentation The hypertension epidemiology section provides insights into the historical and current hypertension patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The hypertension market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Hypertension Diagnosed Prevalent Cases Hypertension Age-specific Diagnosed Prevalent Cases Hypertension Severity-specific Diagnosed Prevalent Cases Hypertension Treatment Market Hypertension is often treated with a combination of lifestyle changes and medication. Adopting a low-sodium, nutritious diet, engaging in regular physical activity, keeping a healthy weight, limiting alcohol consumption, and quitting smoking are all examples of lifestyle modifications. Blood pressure medications such as diuretics, beta-blockers, ACE inhibitors, ARBs, and calcium channel blockers can be administered. Individuals with hypertension can effectively control their illness and reduce the risk of consequences by using these measures. Adherence to lifestyle changes and medicine might be difficult due to a variety of issues such as time constraints, a lack of enthusiasm, and the patient's forgetful disposition. In addition to lifestyle modifications and medication, hypertension treatment may also involve addressing underlying health conditions that contribute to high blood pressure. For instance, if hypertension is caused by an underlying condition such as kidney disease or hormonal disorders, treating or managing these conditions becomes an integral part of the overall treatment plan. Furthermore, patient education and self-care play crucial roles in hypertension treatment. Individuals with high blood pressure are often advised to monitor their blood pressure at home using home blood pressure monitors and to keep track of their readings. This empowers patients to actively participate in their own care and enables them to recognize any abnormal patterns or fluctuations in blood pressure. To know more about hypertension treatment, visit @ Hypertension Treatment Drugs Key Hypertension Therapies and Companies JV-GL1: JeniVision, Inc. AGN-193408 SR: AbbVie Ralinepag: United Therapeutics Hypertension Market Dynamics The dynamics of the hypertension market are expected to change in the coming years. The rising prevalence of the disease is the prominent factor boosting the growth of the hypertension market. In addition, the increase in healthcare spending and rising R&D activities are also likely to propel the hypertension market in the next few years. Furthermore, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the hypertension market in the 7MM. However, several factors are impeding the growth of the hypertension market. The hypertension market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the hypertension market growth. Key Hypertension Companies JeniVision, Inc., AI Therapeutics, Inc., Apnimed, AstraZeneca, Aerovate Therapeutics, Merck Sharp & Dohme LLC, AbbVie, Alnylam Pharmaceuticals, Gossamer Bio Inc., Insmed Incorporated, Actelion, Boehringer Ingelheim, Acceleron Pharma, Bayer, Perfuse Therapeutics, Inc., KBP Biosciences, Novartis, Gmax Biopharm LLC, United Therapeutics, Tarsier Pharma, and others Key Hypertension Therapies JV-GL1, LAM-001, AD113, AZD3427, AV-101, CIN-107, MK-5475, AGN-193408 SR, ALN-AGT01, GB002, Treprostinil Palmitil, Macitentan, BI 685509, Sotatercept, BAY63-2521, PER-001, KBP-5074, LTP001, Q4W GMA301 IV injections, Ralinepag, TRS01, and others Scope of the Hypertension Market Report Therapeutic Assessment: Hypertension current marketed and emerging therapies Hypertension Market Dynamics: Conjoint Analysis of Emerging Hypertension Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Hypertension Market Access and Reimbursement Discover more about hypertension drugs in development @ Hypertension Clinical Trials Table of Contents Hypertension Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertension companies, including Quantum Genomics, CinCor Pharma, Mineralys Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision, Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics, Inc., Aadi Bioscience, Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma, LLC, PolyActiva Pty Ltd, pH Pharma, Nicox Ophthalmics, Inc., Ocular Therapeutix, Inc., Santen SAS, Whitecap Biosciences, LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co., Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IlDong Pharmaceutical Co Ltd, Qlaris Bio, Inc., Santen Pharmaceutical, VivaVision Biotech, Mitsubishi Chemical Group Corporation., Idorsia Pharmaceuticals, United Therapeutics Corporation, VIVUS LLC., PhaseBio Pharmaceuticals, Vascular Biosciences, CAR peptide, Liquidia Corporation, Centessa Pharmaceuticals, Claritas Pharmaceuticals, Halo Biosciences, PulmoSIM Therapeutics, Keros Therapeutics, among others. Pulmonary Hypertension Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Reata Pharmaceuticals, Pharmosa BioPharm, United Therapeutics Corporation, Acceleron Pharma, Bellerophon Therapeutics, Dong-A ST, Mezzion, Northern Therapeutics, Merck Sharp & Dohme Corp., Apeiron Biologics, VIVUS, Respira Therapeutics, Resverlogix, Bial - Portela C S.A., Vigonvita Life Sciences, Altavant Sciences, Roche, PhaseBio Pharmaceuticals, Gossamer Bio, Reviva Biopharmaceuticals, Cereno Scientific, Attgeno, Rho Federal Systems Division, Inc., Cumberland Pharmaceuticals, AstraZeneca, Aerovate Therapeutics, Celon Pharma, Camurus, ATXA Therapeutics, Gmax Biopharma, Aerami Therapeutics, Pfizer, Aadi Biosciences, SystImmune, Claritas Pharmaceuticals, Reviva Biopharmaceuticals, Aqualung Therapeutics, Pulmokine, Recursion Pharmaceuticals, among others. Pulmonary Arterial Hypertension Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key pulmonary arterial hypertension companies, including Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, among others. Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pulmonary arterial hypertension companies including Merck, United Therapeutics, Liquida Technologies, Tenax Therapeutics, Respira Therapeutics, Gossamer Bio, Pharmosa Biopharma, Aerovate Therapeutics, Insmed, Novartis, Cumberland Pharmaceuticals, Enzyvant Therapeutics, AstraZeneca, Cereno Scientific, PhaseBio Pharmaceutical, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us
PhaseBio Pharmaceuticals Frequently Asked Questions (FAQ)
When was PhaseBio Pharmaceuticals founded?
PhaseBio Pharmaceuticals was founded in 2002.
Where is PhaseBio Pharmaceuticals's headquarters?
PhaseBio Pharmaceuticals's headquarters is located at 1 Great Valley Parkway, Malvern.
What is PhaseBio Pharmaceuticals's latest funding round?
PhaseBio Pharmaceuticals's latest funding round is IPO.
How much did PhaseBio Pharmaceuticals raise?
PhaseBio Pharmaceuticals raised a total of $144.94M.
Who are the investors of PhaseBio Pharmaceuticals?
Investors of PhaseBio Pharmaceuticals include Johnson & Johnson Innovation, New Enterprise Associates, Fletcher Spaght Ventures, Hatteras Venture, AstraZeneca and 10 more.
Who are PhaseBio Pharmaceuticals's competitors?
Competitors of PhaseBio Pharmaceuticals include Aphios, Bird Rock Bio, Catalyst Biosciences, Aerie, LungLife AI and 14 more.
Compare PhaseBio Pharmaceuticals to Competitors
Aphios is a clinical stage biotechnology company. It develops technology platfroms to improve drug discovery and manufacturing, nanotechnology drug delivery and pathogenic safety. Based on these platforms, the company develops therapeutics to prevent disease, maintain health, and treat chronic diseases, including cancers and supportive care, infectious diseases such as HIV/AIDS, influenza and COVID-19. The company was founded in 2018 and is based in Woburn, Massachusetts.
Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.
TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging
Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.
Hawaii Biotech (HBI) is a privately held biotechnology company focused on the research and development of vaccines for established and emerging infectious diseases. The company has developed expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. Lead vaccine candidates in clinical development target the West Nile virus and Dengue virus. Additional recombinant protein subunits vaccine candidates produced from this protein production platform are currently under development.
AM-Pharma is a biopharmaceutical company that focuses on the development of recombinant Alkaline Phosphatase for clinical use.